Drug Trial Radar · NCT05334108
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
Last checked: Nov 19, 2026Latest source record: Dec 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Apr 26, 2022
Primary completion
Aug 1, 2022
Study completion Aug 26, 2022
Sponsor
- Lead sponsor
- Emalex Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc; Nuventra, Inc.
- First posted
- Apr 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
Conditions
- Drug Interaction
Interventions
EcopipamDrug
ecopipam HCl \~2mg/kg/day
Cohort 1 Probe Substrate CocktailCombination product
dextromethorphan, caffeine, omeprazole, and midazolam
Cohort 2 Probe SubstrateDrug
bupropion
Cohort 3 Probe Substrate CocktailCombination product
dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
- Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
- Cmax of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
- Cmax oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
- Cmax of dabigatran in the presence of ecopipamTime frame: Up to Day 22
- Cmax of dabigatran in the absence of ecopipamTime frame: Up to Day 22
- Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
- Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
- Cmax of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
- Cmax of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
- Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
- Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUCinf of dabigatran in the presence of ecopipamTime frame: Up to Day 22
- AUCinf of dabigatran in the absence of ecopipamTime frame: Up to Day 22
- AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUCinf of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
- AUCinf of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
- AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUClast of dabigatran in the presence of ecopipamTime frame: Up to Day 22
- AUClast of dabigatran in the absence of ecopipamTime frame: Up to Day 22
- AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUClast of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
- AUClast of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
- AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUC0-24 of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUC0-24 of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUC0-24 of dabigatran in the presence of ecopipamTime frame: Up to Day 22
- AUC0-24 of dabigatran in the absence of ecopipamTime frame: Up to Day 22
- AUC0-24 of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUC0-24 of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
- AUC0-24 of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
- AUC0-24 of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
- AUC0-24 of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
- AUC0-24 of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Early Phase Services
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.